Gujarat Themis Biosyn Ltd: Shareholders Approve Special Resolution for Director Appointment
Gujarat Themis Biosyn Limited shareholders approved the appointment of Mr. Rajneesh Anand as Non-Executive Non-Independent Director via postal ballot and e-voting. The resolution passed with 77,218,083 votes in favour out of 77,954,837 total votes polled.
The appointment of a director is a significant corporate action that can influence future strategy and governance, warranting a medium impact assessment.
The appointment of a new director and the approval of a special resolution by shareholders is generally a positive development for corporate governance and strategic direction.
Gujarat Themis Biosyn Limited announced the voting results and the Scrutinizer’s Report concerning a postal ballot conducted via remote e-voting. The shareholders have approved a special resolution to appoint Mr. Rajneesh Anand (DIN: 00134856) as a Non-Executive Non-Independent Director.
The postal ballot notice was issued on January 2, 2026. The voting results, dated February 7, 2026, indicate that the proposed resolution received the requisite majority from the shareholders through the remote e-voting process. The total votes polled in favour of the resolution were 77,218,083, with 3,423,538 votes against. The percentage of votes in favour on votes polled was 95.7056%, and against was 4.2944%.
Detailed voting data shows that out of 108,965,265 shares held, 77,954,837 votes were polled. The e-voting mechanism recorded 76,642,537 votes in favour and 0 against, representing 100% of the votes polled via this mode. The resolution passing is a significant step in the company's board reconstitution. The voting results and the Scrutinizer’s Report will be made available on the company's website.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under board changes. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.